期刊文献+

溃疡性结肠炎患者骨密度变化的研究 被引量:2

CHANGES IN BONE MINERAL DENSITY IN PATIENTS WITH ULCERATIVE COLITIS STUDY
下载PDF
导出
摘要 目的探讨溃疡性结肠炎骨密度降低和骨质疏松的相关因素分析。方法DPX-NT双能X线骨密度仪对入选的溃疡性结肠炎病人和健康对照组进行骨密度测量和实验室指标的检测。结果在UC患者中,激素治疗患者t值明显偏低,t值与激素累计量呈负相关。轻、中、重度三组UC患者t值差异无统计学意义。溃疡性结肠炎组血钙、ALP、血磷、白蛋白与对照组相比差异无显著性。结论UC患者骨密度下降、骨质疏松和骨量减少的发生与皮质类固醇激素的应用有关,与病情轻重和实验室指标无相关性。 Objective Discussion ulcerative colitis and osteoporosis to reduce bone mineral density analysis of related factors. Methods DPX - NT Dual - energy X - ray absorptiometry for sdected patients with ulcerative colitis and healthy control group bone mineral density measurement and laboratory testing. Results In UC patients, Hormone therapy was significantly lower in patients with T,T value and the cumulative amount of hormone was negatively correlated. Light,moderate and severe UC in patients with three groups of T the value of the difference was not statistically sigrdfieant. Ulcerative colitis group of calcium, ALP, phosphorus, albumin, compared with the control group there was no significant difference. Conclusion UC patients with decreased bone mineral density, osteoporosis and bone mass and reduce the occurrence of eortieostereid application,with the severity and laboratory indicators of no relevance.
出处 《现代医院》 2009年第9期37-38,共2页 Modern Hospitals
关键词 溃疡性结肠炎 骨密度 骨质疏松 皮质类固醇激素 Ulcerative Culitis, Bone mineral density, Osteoporosis, Corticesteroids
  • 相关文献

参考文献8

  • 1ADACHI J D, ROSTOM A. Metabolic bone disease in adults with inflammatory bowel disease[ J]. Inflamm Bowel Dis, 1999,5:200 -211.
  • 2ARDIZZONE S,BOLLANI S,BETTICA P,et al. Alter bone metabolism in inflammatory bowel dise - ase: there is a difference between Crohn' s disease and ulcerative colitis [J]. J Intern Mcd, 2000,247:63- 70.
  • 3欧阳钦,潘国宗,温忠慧,万学红,胡仁伟,林三仁,胡品津.对炎症性肠病诊断治疗规范的建议[J].中华消化杂志,2001,21(4):236-239. 被引量:1123
  • 4中国人原发性骨质疏松症诊断标准(试行)[J].中国骨质疏松杂志,1999,5(F03):1-3. 被引量:325
  • 5TRUELOVE S C,WITTS L J. Cortisone in ulcerative colitis;final report on a therapeutic trial [ J]. Br Med J, 1955,2:1041 -1048.
  • 6KALLIS J A, GERTZ B J ,SINGER F,et al. Rationale for the use of alendronate in osteoporosis [ J]. Osteoporosis Int. 1995,5 : 1.
  • 7BERNSTEIN C N, LESLIE W D. Reviewarticle: Osteoporosis and innammatory bowel disease [ J]. Ailment Pharmacol Ther, 2004, 19:941 - 952.
  • 8FREI P, FRIED M, HUNGERBUHLER V, et al. Analysis of riskfactors for lowbone mineral density in inflammatory bowel disease [ J ]. Digestion,2006,73:40 - 46.

共引文献1446

同被引文献10

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部